Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.
Zevra Therapeutics prices rare genetic disorder drug at up to $106,000 per month
Zevra Therapeutics' drug, Miplyffa, for treating a rare and fatal genetic disorder will have a wholesale acquisition cost ranging between $40,000 and $106,000 per month depending on dosage, the ...
pharmaphorum5h
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...
The Pharma Letter6h
Sanofi’s Sarclisa gains third FDA approval
The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...
Medscape7h
Isatuximab Approved First-Line for Transplant-Ineligible MM
In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...